Jason Bradt

Statistics

Publications

Citations

261

H-Index

Active since

2014

Affiliations

Frederick National Laboratory for Cancer Research(Current)

Charles University

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Erasmus MC

Jason Bradt is an author at Frederick National Laboratory for Cancer Research specializing in pi3k signaling, phosphoinositide 3-kinase signaling, and clinical pharmacology.

Publications per year

2014–2024

Publications

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

V. Koneti Rao, Sharon Webster, Anna Šedivá et al. · Blood · 2022 · 132 citations · Full text

Medicine, Immunology, Pharmacology +13

Interim analysis: Open-label extension study of leniolisib for patients with APDS

V. Koneti Rao, Elaine Kulm, Anna Šedivá et al. · Journal of Allergy and Clinical Immunology · 2023 · 40 citations · Full text

Medicine, Immunology, Pharmacology +15

A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy

Fernando J. Bianco, David Albala, Laurence Belkoff et al. · The Journal of Urology · 2014 · 33 citations

Medicine, Surgery, Urology +17

Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder

Brandon T. Suehs, Cralen Davis, Billy Franks et al. · Journal of the American Geriatrics Society · 2016 · 26 citations

Pharmacy, Geriatric Medicine, Pharmacoeconomics +17

Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome

V. Koneti Rao, Elaine Kulm, Jennifer Grossman et al. · Blood Advances · 2024 · 15 citations · Full text

Life Sciences, Immunology, Pharmacology +14

1–5 of 6